Praxis Begins Patient Recruitment for Pediatric Epilepsy Research Program
Brentwood, TN
Praxis a company specializing in centralized patient recruitment and retention for clinical research studies, will provide patient recruitment services to a top pharmaceutical company for a study on pediatric epilepsy. This study explores a drug’s effectiveness in very young children. Praxis’ experiences with hard to reach and specialized patient populations is extensive and includes a number of pediatric trials.
Praxis’ successful experiences with hard to reach and specialized patient populations is extensive, and includes a number of pediatric trials. Praxis has helped sponsors successfully enroll pediatric studies:
on average 2 months ahead of schedule
with retention rates most often at 96%, and
with sponsors achieving ROI from ~$1M to ~$3M
“Any time we create and manage a trial involving children there is a real added focus on understanding the mother’s perspective and concerns. We seek to really connect with the mother through images and words that speak to the heart. And by providing content that educates and informs the mom about options, the indication, and the medical research study at hand.” Donna Beasley, VP of operations.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
